SOLV · Solventum Corp
Price
Snapshot
50 fields · last close| Market Cap | $14.61B |
| P/E | 10.18 |
| Float | 147.1M |
| Beta | 0.75 |
| Volatility | 18.7% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 80.5 |
| Price | 85.70 |
| Change | −0.13% |
| Prev Close | 85.81 |
| Open | 88.42 |
| Day Low | 85.18 |
| Day High | 89.00 |
| Avg Vol | 1 |
| Avg $ Vol | $95.01M |
| 52W High | 94.16 |
| 52W Low | 62.38 |
| 52W Pos | 73.4% |
| From High | −8.98% |
| From Low | +37.38% |
| Max DD 1Y | −27.46% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −2.27% |
| SMA 50 | −3.09% |
| SMA 200 | +9.51% |
| RSI (14) | 42.4 |
| Vol 30D | 19.6% |
| Vol 90D | 28.5% |
| 1Y Range | 62–94 |
| Daily bars | 536 |
| Perf Week | −1.70% |
| Perf Month | −1.97% |
| Perf Quarter | +8.28% |
| Perf Half Y | +21.75% |
| Perf Year | +19.91% |
| Perf YTD | +8.45% |
| Prev Day | −0.13% |
| Clavix | B+ |
| Debt / Eq | 1.00 |
| Curr Ratio | 1.23 |
| Int Cover | 7.7× |
| FCF Margin | −0.1% |
| Rev Growth | +0.9% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 14 / 49 |
What SOLV does
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.
It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V.
site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers.
The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs.
The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms.
The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce.
Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
Clavix risk grade
regraded every trading daySOLV grades B+, 80.5 of 100. Steadiest on Macro Resilience (68), most exposed on Sector Resilience (62, mixed). 2 of the 3 weighted dimensions sit above the Health Care median. Ranks 14 of 49 in Health Care by Clavix score.
How rough the ride is
| SOLV | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.75 | 0.84 |
| Volatilityannualized | 18.7% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −27.5% | — |
| Typical daily movemedian absolute daily change | 1.11% | — |
| Days beyond ±3%of the last 252 sessions | 19 (8%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| SOLV | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.75 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| SOLV | |
|---|---|
| 1 week | −1.7% |
| 1 month | −2.0% |
| Year to date | +8.5% |
| 1 year | +19.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| SOLV | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 5 Aug |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 1 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| SOLV | |
|---|---|
| Revenue growthyear over year | +0.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openTwelve analysts covering Solventum Corporation (SOLV) have given it an average 'Moderate Buy' rating, with one sell, three hold, and eight buy-equivalent ratings. The article is truncated and does not provide further detail.
Solventum has lagged behind other healthcare stocks over the past year, but analysts remain fairly optimistic, citing the stock's bullish momentum and a positive outlook.
The article recommends holding Solventum (SOLV) stock, citing its strong second-quarter results, ongoing investments in growth, and a cost-saving program as reasons to stay invested, while flagging higher raw material costs as a concern.
An analyst-style article argues Solventum's stock is worth holding because of strong second-quarter results, ongoing growth investments, and a cost-cutting program, while flagging higher raw material costs as a risk.
Solventum reported quarterly results that beat analyst expectations on both organic revenue and earnings per share, with management highlighting strong execution and ongoing transformation. The company also pointed to its surgical equipment and consumables business, including AI and robotics-enabled products, as supporting steady procedural demand.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BAX | Baxter International Inc | B | $13.07B | — | 0.66 | Compare |
| PEN | Penumbra Inc | A+ | $12.64B | 78.70 | 0.69 | Compare |
| BTSG | Brightspring Health Services Inc | B- | $12.04B | 32.91 | 1.88 | Compare |
| DVA | DaVita Inc | B | $11.95B | 14.10 | 0.87 | Compare |
| ZBH | Zimmer Biomet Holdings, Inc | B+ | $18.37B | 22.38 | 0.49 | Compare |
| COO | Cooper Companies Inc | B- | $11.02B | 19.32 | 0.82 | Compare |
| UHS | Universal Health Services Inc | A- | $10.91B | 7.15 | 1.11 | Compare |
| MOH | Molina Healthcare Inc | B | $10.82B | 22.93 | 0.73 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.